C. Lacerte

Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms

K. Brouwer, K. Brouwer, Cen Guo, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage

D. Shapiro, T. Peyret, C. Lacerte, 2016, Clinical and translational science.

Low‐dose Pramlintide Reduced Food Intake and Meal Duration in Healthy, Normal‐Weight Subjects

S. Doran, J. Wishart, M. Horowitz, 2007, Obesity.

Quantitative Gene Expression Assays without Target Amplification

A. Lois, C. Lacerte, J. Tolley, 2003 .

Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients

V. Ivaturi, J. Gobburu, L. Doyle, 2017, Clinical Cancer Research.

The glucagon‐like peptide‐1‐based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys

D. Parkes, R. Mangipudy, T. Reilly, 2014, Diabetes, obesity & metabolism.

A high-capacity assay for PPARgamma ligand regulation of endogenous aP2 expression in 3T3-L1 cells.

J. Berger, L. Kelly, C. Biswas, 2004, Analytical biochemistry.

Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models

S. Kansra, Yuanyuan Zhang, K. Brouwer, 2017, Pharmacology research & perspectives.

Rapid assays for quantitating cytokine gene expression without target amplification.

A. Lois, C. Lacerte, J. Tolley, 2003, Combinatorial chemistry & high throughput screening.